Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vera Therapeutics Inc Cl A (VERA)

Vera Therapeutics Inc Cl A (VERA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,772,895
  • Shares Outstanding, K 71,356
  • Annual Sales, $ 0 K
  • Annual Income, $ -299,610 K
  • EBIT $ -315 M
  • EBITDA $ -320 M
  • 60-Month Beta 1.17
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.75

Options Overview Details

View History
  • Implied Volatility 85.57% (+4.76%)
  • Historical Volatility 41.06%
  • IV Percentile 49%
  • IV Rank 22.94%
  • IV High 228.19% on 05/30/25
  • IV Low 43.10% on 08/21/25
  • Expected Move (DTE 18) 4.38 (11.49%)
  • Put/Call Vol Ratio 0.28
  • Today's Volume 37
  • Volume Avg (30-Day) 991
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 18,023
  • Open Int (30-Day) 18,587
  • Expected Range 33.72 to 42.48

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -1.26
  • Number of Estimates 5
  • High Estimate -1.16
  • Low Estimate -1.35
  • Prior Year -0.81
  • Growth Rate Est. (year over year) -55.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.51 +1.57%
on 03/19/26
45.38 -16.03%
on 03/10/26
-2.69 (-6.59%)
since 02/27/26
3-Month
37.51 +1.57%
on 03/19/26
53.76 -29.13%
on 12/29/25
-15.48 (-28.89%)
since 12/26/25
52-Week
18.53 +105.61%
on 04/09/25
56.05 -32.02%
on 12/24/25
+11.47 (+43.07%)
since 03/28/25

Most Recent Stories

More News
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on March 23, 2026, the Compensation Committee of the Board of Directors (Compensation...

VERA : 38.10 (-1.96%)
Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer

BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with...

VERA : 38.10 (-1.96%)
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on March 3, 2026, the Compensation Committee of the Board of Directors (Compensation...

VERA : 38.10 (-1.96%)
Vera Therapeutics Appoints Christopher Hite to Board of Directors

BRISBANE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with...

VERA : 38.10 (-1.96%)
Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results

Positive Phase 3 data from ORIGIN 3 study of atacicept in IgA nephropathy (IgAN) presented at American Society of Nephrology (ASN) Kidney Week and published in the New England Journal of Medicine U.S....

VERA : 38.10 (-1.96%)
Vera Therapeutics to Participate at Upcoming Investor Conferences

BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments...

VERA : 38.10 (-1.96%)
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on February 2, 2026, the Compensation Committee of the Board of Directors (Compensation...

VERA : 38.10 (-1.96%)
Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer

BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments...

VERA : 38.10 (-1.96%)
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on January 5, 2026, the Compensation Committee of the Board of Directors of Vera Therapeutics...

VERA : 38.10 (-1.96%)
Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative...

VERA : 38.10 (-1.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Vera Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Vera Therapeutics Inc. is based in SOUTH SAN FRANCISCO, Calif.

See More

Key Turning Points

3rd Resistance Point 39.95
2nd Resistance Point 39.50
1st Resistance Point 38.80
Last Price 38.10
1st Support Level 37.65
2nd Support Level 37.20
3rd Support Level 36.50

See More

52-Week High 56.05
Fibonacci 61.8% 41.72
Last Price 38.10
Fibonacci 50% 37.29
Fibonacci 38.2% 32.86
52-Week Low 18.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.